Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma

Ilya Tsimafeyeu , Alexander Sultanbaev , Daria Dubovichenko , Makhabbat Murzalina , Alexander Volkov , Rashida Orlova , Igor Utyashev , Georgy Malina , Mark Gluzman

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002305

PDF (1385KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002305 DOI: 10.37349/etat.2025.1002305
Short Communication
research-article
Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma
Author information +
History +
PDF (1385KB)

Abstract

The combination of lenvatinib and pembrolizumab (Len + Pembro) demonstrated significant efficacy in the phase 3 CLEAR study for metastatic renal cell carcinoma (RCC). However, poor-risk patients represented only a small proportion of the trial population. This multicenter retrospective cohort study assessed the real-world efficacy and safety of Len + Pembro in patients with clear-cell metastatic RCC and intermediate or poor International Metastatic RCC Database Consortium risk. Outcomes included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Sixty patients were analyzed, with a median age of 56 years. Poor risk was identified in 53% of patients, and 90% had metastases to ≥ 2 organs. ORR was 48.33%, disease control rate was 86.7%, and median PFS was 19.0 months. Grade ≥ 3 adverse events occurred in 25% of patients, with 33.3% requiring lenvatinib dose reductions. Lenvatinib plus pembrolizumab demonstrated robust efficacy and a manageable safety profile in a real-world population with advanced disease and poor-risk features, consistent with outcomes reported in clinical trials.

Keywords

Metastatic renal cell carcinoma / lenvatinib plus pembrolizumab / real-world evidence / IMDC intermediate and poor risk

Cite this article

Download citation ▾
Ilya Tsimafeyeu, Alexander Sultanbaev, Daria Dubovichenko, Makhabbat Murzalina, Alexander Volkov, Rashida Orlova, Igor Utyashev, Georgy Malina, Mark Gluzman. Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002305 DOI:10.37349/etat.2025.1002305

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Tsimafeyeu I, Zolotareva T, Varlamov S, Zukov R, Petkau V, Mazhbich M, et al. Five-year Survival of Patients With Metastatic Renal Cell Carcinoma in the Russian Federation: Results From the RENSUR5 Registry. Clin Genitourin Cancer. 2017; 15: e1069-72.

[2]

Tsimafeyeu I, Shatkovskaya O, Krasny S, Nurgaliev N, Varlamov I, Petkau V, et al. Overall survival in patients with metastatic renal cell carcinoma in Russia, Kazakhstan, and Belarus: a report from the RENSUR3 registry. Cancer Rep (Hoboken). 2021; 4:e1331.

[3]

Barragan-Carrillo R, Saad E, Saliby R, Sun M, Albiges L, Bex A, et al. First and Second-line Treatments in Metastatic Renal Cell Carcinoma. Eur Urol. 2025; 87: 143-54.

[4]

Motzer RJ, Porta C, Eto M, Hutson TE, Rha SY, Merchan JR, et al. Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma. Ann Oncol. 2025; 36: 375-86.

[5]

Choueiri TK, Eto M, Motzer R, Giorgi UD, Buchler T, Basappa NS, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023; 24: 228-38. Erratum in: Lancet Oncol. 2023; 24:e146.

[6]

Motzer RJ, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, et al. ; CLEAR Trial Investigators. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol. 2024; 42: 1222-8.

[7]

Hara T, Suzuki K, Okamura Y, Chiba K, Sato R, Matsushita Y, et al. Efficacy and safety of lenvatinib and pembrolizumab as first-line treatment for advanced renal cell carcinoma patients: real-world experience in Japan. Int J Clin Oncol. 2024; 29: 1931-6.

[8]

Dutcher JP, Flippot R, Fallah J, Escudier B. On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment-Cytokines, Targeted Therapy, and Immunotherapy. Am Soc Clin Oncol Educ Book. 2020; 40: 1-18.

[9]

Roskoski R Jr. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas. Pharmacol Res. 2024; 203: 107181.

[10]

Grünwald V, Powles T, Eto M, Kopyltsov E, Rha SY, Porta C, et al. Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front Oncol. 2024; 13: 1343027. Erratum for: Front Oncol. 2023; 13:1223282.

PDF (1385KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉